This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:

Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms

https://www.ncbi.nlm.nih.gov/pubmed/30819281

New-Onset Asthma in Adults: What Does the Trigger History Tell Us?

https://www.ncbi.nlm.nih.gov/pubmed/30240884

Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States

https://www.ncbi.nlm.nih.gov/pubmed/30277796

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.